Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...
The Manila Times6d
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
Yahoo Finance6d
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™
With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis." MASH has long been a challenging and progressive liver disease, characterized by ...
Le Lézard6d
A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHTtm
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
European Medical Journal5d
Machine Learning in Liver Fibrosis Diagnosis and Progression
Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...